Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 513-518

  Kimura, Tatsuo ^a   Kudoh, Shinzoh ^a   Mitsuoka, Shigeki ^a   Yoshimura, Naruo ^b   Tanaka, Hidenori ^a   Asai, Kazuhisa ^a   Kyoh, Shigenori ^a   Tochino, Yoshihiro ^a   Umekawa, Kanako ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Otemae Hospital   (Japan)

Author keywords

Amrubicin; Amrubicinol; Anthracycline; Lung cancer; Pharmacodynamics; Plasma concentration; Topoisomerase II inhibitor

Indexed keywords

AMRUBICIN; AMRUBICINOL; CISPLATIN; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL COUNT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THYMUS CANCER;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 67249146025     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832b0585     Document Type: Article

References (19)

1. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998; 89:1229-1238. (Pubitemid 29008005)
2. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89:1067-1073. (Pubitemid 28544784)
3. Okamoto I, Hamada A, Matsunaga Y, Sasaki J, Fujii S, Uramoto H, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9- aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006; 57:282-288.
4. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24:5448-5453. (Pubitemid 46623179)
5. Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A, et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007; 2:741-744. (Pubitemid 47357529)
6. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005; 16:430-436. (Pubitemid 40458320)
7. Ikeda J, Maruyama R, Okamoto T, Shoji F, Wataya H, Ichinose Y. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer. Jpn J Clin Oncol 2006; 36:12-16. (Pubitemid 43210730)
8. Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer 2006; 53:189-195. (Pubitemid 43994239)
9. Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H, et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 2006; 28:76-82. (Pubitemid 44391698)
10. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998; 89:1061-1066. (Pubitemid 28544783)
11. Yanaihara T, Ybkoba M, Onoda S, Yamamoto M, Ryuge S, Hagiri S, et al. Phase 1 and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2007; 59:419-427. (Pubitemid 46122320)
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
13. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 1995; 37:23-31.
14. Beelen AP, Lewis LD. Clinical pharmacology overview. In: Figg WD, McLeod HL, editors. Handbook of anticancer pharmacokinetics and pharmacodynamics. Totowa: Humana Press Inc.; 2004. pp. 111-127.
15. Kudoh S, Yoshimura N, Kimura T, Mitsuoka S, Hirata K. A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2006; 24:abstr 17053.
16. Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Yana T, Hirata K. Phase I study of amrubicin and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2008; 26:abstr 19119.
17. Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med 1979; 300:289-291.
18. Johnsson A, Hoglund P, Grubb A, Cavallin-Stahl E. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol 1996; 39:25-33. (Pubitemid 26400657)
19. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol 2004; 22:2901-2908. (Pubitemid 41079910)